/ /

  • linkedin
  • Increase Font
  • Sharebar

    MIGS stent yields good IOP control as stand-alone treatment

    DUETTE trial for patients refractory to glaucoma medications showed less drug burden


    The device is surgically implanted into the supraciliary space of the eye through a small corneal incision, Dr. Nguyen explained.

    The average patient age was 68, and the mean baseline was 24.5 mm Hg. Although the mean number of baseline medications was 2.2, 37% of those included in the trial used three or more medications. Sixty-three percent of patients were phakic.

    Regarding patient safety, no sight-threatening complications or serious adverse events occurred.

    “Seven patients had an IOP spike that resolved,” Dr. Nguyen said.

    There were smaller numbers of patients that experienced transient hyphema, cataract progression, peripheral anterior synechiae, or a best-corrected visual acuity loss of two lines or greater. Seventeen percent of patients went on to require a trabeculectomy; 6% exited the study by choice, and 4.6% were lost to follow up.

    Data at 1 year

    There was a 30% decrease in mean IOP from baseline (24.5 mm Hg) to 6 months (17.7 mm Hg) to 1 year (16.7 mm Hg), Dr. Nguyen said, adding that the 1-year number reflects a total of 47 patients versus the 65 from baseline.

    The mean number of medications needed dropped from 2.2 to 1.3 at 6 months and 1.5 at 1 year.

    “With 1 year of data, using the CyPass as a stand-alone procedure shows good IOP control with less medication burden,” Dr. Nguyen said. “It’s relatively safe, and it’s very easy to implant. There is a quick learning curve, and it can offer good IOP reduction as a stand-alone procedure,” Dr. Nguyen concluded.


    Quang H. Nguyen, MD

    E: [email protected]

    This article was adapted from Dr. Nguyen’s presentation during the 2014 meeting of the American Academy of Ophthalmology. Dr. Nguyen and co-researchers are investigators for Transcend Medical.




    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results